Universal Health Services, Inc. (UHS) Stock Price & Analysis
Universal Health Services, Inc. (UHS) closed at USD 188.13 on Thursday, October 22, 2026, up 2.88% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 182.87; the Oct 22, 2026 session ranged USD 182.94–188.86 on volume of 489,111 shares. Market capitalization is $11.09B, with a 52-week range of USD 140.08–246.33 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/UHS.md
Key facts (UHS)
- Last four reported quarters (through Jun 30, 2026): revenue $18.1B, net income $1.53B (8.4% margin), free cash flow $845M (SEC filings).
- Valuation: P/E 7.3x (avg 11.7x at the last 3 fiscal year-ends), EV/EBITDA 5.9x, net debt $4.76B.
- 2 of 80 tracked superinvestors hold UHS (13F, Q2 2026): 0 new, 2 added, 0 reduced, 0 unchanged.
- Analysts: Hold (mean 2.80 on a 1–5 scale) (20 analysts), mean target USD 196.12 (range 166–290).
- Total return with dividends: 1Y -9.4% vs S&P 500 +14.9%; 5Y +42.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 5.15, revenue estimate $4.71B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (UHS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.6B | $13.4B | $14.3B | $15.8B | $17.4B | $18.1B |
| Operating income | $1.36B | $1.00B | $1.18B | $1.68B | $1.99B | $2.06B |
| Net income | $992M | $676M | $718M | $1.14B | $1.49B | $1.53B |
| EPS (diluted) | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 | — |
| Free cash flow | $28.0M | $262M | $525M | $1.12B | $849M | $845M |
| Operating margin | 10.8% | 7.5% | 8.2% | 10.6% | 11.5% | 11.4% |
| Net margin | 7.8% | 5.0% | 5.0% | 7.2% | 8.6% | 8.4% |
| Revenue growth | +9.4% | +6.0% | +6.6% | +10.8% | +9.7% | — |
| Cash + short-term investments | $115M | $103M | $119M | $126M | $138M | — |
| Total debt | $4.19B | $4.81B | $4.91B | $4.50B | $4.80B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (UHS)
P/E 7.3x · P/S 0.6x · EV/EBITDA 5.9x · EV/Sales 0.9x · P/FCF 13.1x · P/B 1.5x · FCF yield 7.62% · Earnings yield 13.76% · Dividend yield (paid, TTM) 0.45% · Buyback yield (TTM) 9.69% · Net debt $4.76B · EV $15.8B
P/E at fiscal year-ends: Dec 2025 9.4x, Dec 2024 10.7x, Dec 2023 14.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (UHS)
2 of 80 tracked investors hold UHS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 1.13% | $677M | Added +3.0% |
| Richard Pzena | Pzena Investment Management | 0.86% | $293M | Added +3.0% |
Analysts (UHS)
Consensus Hold (mean 2.80 on a 1–5 scale), 20 analysts; mean target USD 196.12 (low 166, high 290).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | Leerink Partners | Target raised | Outperform | $198 → $205 |
| 2026-08-20 | RBC Capital | Reiterated | Sector Perform | $183 |
| 2026-08-03 | RBC Capital | Target lowered | Sector Perform | $190 → $183 |
| 2026-07-30 | Goldman Sachs | Target lowered | Neutral | $242 → $190 |
| 2026-07-29 | Morgan Stanley | Target lowered | Equal-Weight | $212 → $191 |
| 2026-07-29 | Guggenheim | Target lowered | Buy | $195 → $189 |
| 2026-07-29 | Cantor Fitzgerald | Reiterated | Neutral | $194 |
| 2026-07-29 | Baird | Target lowered | Neutral | $204 → $166 |
| 2026-07-28 | Cantor Fitzgerald | Reiterated | Neutral | $194 |
| 2026-07-28 | Barclays | Target lowered | Equal-Weight | $179 → $168 |
| 2026-07-20 | Guggenheim | Target lowered | Buy | $211 → $195 |
| 2026-07-13 | Wells Fargo | Target raised | Equal-Weight | $165 → $166 |
Total return (dividends reinvested) (UHS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -9.4% | +42.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -9.5% | +7.3% |
| Volatility (annualized) | 32.6% | 33.4% |
| Max drawdown | -42.0% (Nov 2025→Jun 2026) | -41.9% (Nov 2025→Jun 2026) |
Companies that name UHS in their SEC reports
| Relationship to UHS | Company | Filing | Sentence |
|---|---|---|---|
| partner | UNIVERSAL HEALTH REALTY INCOME TRUST (UHT) | 10-K Feb 25, 2026 | “Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, five of our hospital facilities are leased to wholly-owned subsidiaries of UHS, one of our hospital facilities is leased to a joint venture between a wholly-owned subsidiary of UHS and a third party, and subsidiaries of UHS are tenants of nineteen medical office buildings ("MOBs"), free-standing emergency …” |
UHS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $5.15 | $5.56 | -7.3% | $4.71B | 15 |
| Next quarter (ends Dec 2026) | $5.73 | $6.17 | -7.2% | $4.76B | 15 |
| Current fiscal year (ends Dec 2026) | $22.48 | $23.39 | -3.9% | $18.60B | 14 |
| Next fiscal year (ends Dec 2027) | $23.89 | $25.16 | -5.0% | $19.49B | 15 |
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 188.13 |
|---|---|
| Change | ▲ 2.88% (up) |
| Previous Close | USD 182.87 |
| Open | USD 183.36 |
| Day Range | USD 182.94 – 188.86 |
| 52-Week Range | USD 140.08 – 246.33 |
| Volume | 489,111 shares |
| Market Cap | $11.09B |
| Exchange | NYQ |
Technical Analysis (UHS)
Nexqual's technical model rates UHS "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.41 (neutral) |
| vs SMA50 | Above (USD 176.38) |
| MACD | 2.95 (positive) |
Analyst Ratings (UHS)
Wall Street analysts rate UHS "Hold" based on 20 analysts, with a mean price target of USD 196.12 (range USD 166–290), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 196.12 |
| High Target | USD 290 |
| Low Target | USD 166 |
| Buy / Hold / Sell | 6 / 13 / 1 |
Earnings (UHS)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 5.15 |
| Revenue Estimate | $4.71B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 5.98 vs est 6.01 ▼ miss |
| 2026-03-31 | USD 5.62 vs est 5.46 ▲ beat |
| 2025-12-31 | USD 5.88 vs est 5.91 ▼ miss |
| 2025-09-30 | USD 5.69 vs est 4.95 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (UHS)
| Total Revenue | $18.11B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.30% |
| Gross Margin | +44.61% |
| Operating Margin | +11.14% |
| Profit Margin | +8.42% |
| ROE | +20.95% |
| Debt / Equity | 0.69 |
| Current Ratio | 1.12 |
| Total Cash | $138.80M |
| Total Debt | $5.26B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $845.40M (4.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (UHS)
Nexqual rates Universal Health Services, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 45%, operating 11% (last 12 months) |
| Balance Sheet | Solid — $139M cash and investments vs $4.90B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $845M (last 4 quarters to Jun 2026, SEC), slim 4.7% margin |
| Efficiency | Strong — ROE 21%, ROA 8.3% |
Ownership (UHS)
| Insider Ownership | +4.98% |
|---|---|
| Institutional Ownership | +105.79% |
| Shares Outstanding | 51.69M |
| Float | 48.74M |
| Short % of Float | +6.19% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (UHS)
Universal Health Services, Inc. is led by Marc D. Miller, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:25 UTC.
| CEO, President & Director | Marc D. Miller |
|---|---|
| Founder & Executive Chairman of the Board | Alan B. Miller |
| Executive VP, CFO & Secretary | Steve G. Filton |
| Executive VP & President of Acute Care Division | Edward H. Sim |
| Vice President of Investor Relations | Darren P. Lehrich |
Major Backers & Investors (UHS)
Notable institutional backers of Universal Health Services, Inc. include First Eagle Investment Management, LLC, Pzena Investment Management LLC, Invesco, according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 8.81% |
| Pzena Investment Management LLC | 3.81% |
| Invesco | 3.77% |
| FMR, LLC | 2.74% |
| Fidelity | 1.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.3% |
| BlackRock | 7.85% |
| Dimensional Fund Advisors | 4.28% |
| State Street | 4.07% |
| Geode Capital | 3.82% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| FMS | Fresenius Medical Care AG | USD 22.23 | ▲ 3.11% |
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt